Regeneron Pharmaceuticals 8-K, filed Oct 6, 2026

Summary

Regeneron Pharmaceuticals and Sanofi entered a sixth amendment to their antibody license and collaboration agreement on October 1, 2026, under which the companies will co-develop and co-commercialize four new Regeneron-invented antibodies, with Sanofi paying Regeneron a $1.0 billion upfront payment and up to $7.0 billion in aggregate development, regulatory, and commercial milestones, and global profits shared equally. As part of the deal, Regeneron agreed to dismiss its lawsuit over Sanofi's obligation to provide access to material information on Dupixent and other Antibody LCA products, and said it expects a roughly $22 million pre-tax acquired IPR&D charge in the third quarter of 2026, cutting GAAP and non-GAAP diluted EPS by about $0.18.

Key points

• The four antibodies covered are an IL-13 antibody, an IL-4 antibody, an IL-4 receptor alpha antibody, and a bispecific IL-4xIL-13 antibody.
• Regeneron holds an option, exercisable asset-by-asset after certain ongoing trials, to add Sanofi's Phase 2/3 bispecific Nanobody lunsekimig (targeting TSLP and IL-13) and another Sanofi early development product to the collaboration, reimbursing certain development costs if exercised.
• Regeneron will lead development and regulatory work before marketing applications and remain lead regulatory party in the United States; Sanofi will lead regulatory outside the United States and lead commercialization.
• Development costs for all licensed products are shared equally, with costs above a budget cap for the new products borne by Regeneron, subject to recoupment rights.

Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.